Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN – Get Rating) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $2.95. Oragenics shares last traded at $2.73, with a volume of 8,844 shares trading hands.
Oragenics Stock Down 1.4 %
The company has a market cap of $5.35 million, a P/E ratio of -21.00 and a beta of 0.19.
Get Oragenics alerts:Hedge Funds Weigh In On Oragenics
Institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp boosted its stake in Oragenics by 8.1% in the first quarter. State Street Corp now owns 495,563 shares of the biotechnology company's stock worth $171,000 after purchasing an additional 37,338 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Oragenics by 116.5% during the second quarter. Renaissance Technologies LLC now owns 209,600 shares of the biotechnology company's stock worth $73,000 after acquiring an additional 112,800 shares during the last quarter. Finally, Millennium Management LLC raised its position in shares of Oragenics by 591.6% during the second quarter. Millennium Management LLC now owns 128,733 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 110,119 shares during the last quarter. Institutional investors and hedge funds own 9.31% of the company's stock.
Oragenics Company Profile
(Get Rating)
Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Featured Articles
- Get a free copy of the StockNews.com research report on Oragenics (OGEN)
- Dividend King Genuine Parts Company Upgraded On Profit Guidance
- The Bottom Is In For Accenture
- 11 Best Consumer Discretionary Stocks of 2023
- 10 Best Consumer Discretionary ETFs
- 5 Best Dividend Capture Stocks
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.